AI Terminal
Ambu
Management Reports • Jan 5, 2026
3353_rns_2026-01-05_816ca407-de45-4317-bce2-0062a8d6e4d4.pdf
Management Reports
Open in ViewerOpens in native device viewer
{0}------------------------------------------------
REPORTING OF TRANSACTIONS MADE BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES
5.1.2026 13:04:44 CET | Ambu A/S | Managers' Transactions
In accordance with its long-term incentive program ("LTIP") Ambu A/S has allocated performance share units ("PSUs") to the Executive Management and other key employees. Reference is made to the company announcement of 28 July 2023 regarding the initial grant.
Pursuant to the Market Abuse Regulation article 19, Ambu A/S hereby notifies receipt of information of the following transaction(s) made by persons discharging managerial responsibilities in Ambu A/S and/or their closely associated persons related to Ambu A/S's shares admitted to trading and official listing on NASDAQ Copenhagen A/S.
The attached document discloses the data of the transactions made by Executive Management.
Company announcement no. 8 2025/26.
Contacts
- Anders Hjort, Head of Investor Relations, +45 2892 8881, [email protected]
- Tine Bjørn Schmidt, Director of Corporate Communications, +45 2264 0697, [email protected]
About Ambu A/S
Ever since 1937, Ambu has surpassed expectations with groundbreaking solutions that improve patient care. Millions of patients, clinicians, and health systems worldwide rely on our endoscopy, anesthesia, and patient monitoring solutions for efficiency, safety, and performance. Our ownership of every stage of the product life cycle enables us to work closely with healthcare professionals, maintain a reliable product supply, and uphold full transparency. At our headquarters in Copenhagen, Denmark, and around the world in Europe, North America, and the Asia Pacific, 5,200+ Ambu team members are committed to delivering above and beyond.